Addex Therapeutics Ltd (NASDAQ:ADXN) Short Interest Down 23.5% in February

Addex Therapeutics Ltd (NASDAQ:ADXN) was the target of a large drop in short interest during the month of February. As of February 28th, there was short interest totalling 1,300 shares, a drop of 23.5% from the February 13th total of 1,700 shares. Approximately 0.2% of the shares of the company are sold short. Based on an average daily trading volume, of 19,600 shares, the days-to-cover ratio is presently 0.1 days.

Addex Therapeutics Price Performance

Addex Therapeutics stock opened at $7.42 on Wednesday. Addex Therapeutics has a fifty-two week low of $6.67 and a fifty-two week high of $27.90. The firm has a fifty day moving average price of $7.73 and a two-hundred day moving average price of $8.74. The firm has a market cap of $7.87 million, a price-to-earnings ratio of -21.82 and a beta of 1.76.

Hedge Funds Weigh In On Addex Therapeutics

An institutional investor recently bought a new position in Addex Therapeutics stock. Citadel Advisors LLC purchased a new position in Addex Therapeutics Ltd (NASDAQ:ADXN) during the 4th quarter, according to its most recent disclosure with the SEC. The fund purchased 12,079 shares of the company’s stock, valued at approximately $85,000. Citadel Advisors LLC owned 1.14% of Addex Therapeutics as of its most recent SEC filing. 16.14% of the stock is currently owned by institutional investors.

Addex Therapeutics Company Profile

Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia and dystonia, and post-stroke/TBI recovery; ADX71149, a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mGlu2 PAM) for the treatment of epilepsy; and GABAB PAM for the treatment of pain, anxiety, overactive bladder, and addiction, as well as substance use disorder.